HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Paterson, P. Y. Articles by Drobish, D. G. Search for Related Content PubMed Articles by Paterson, P. Y. Articles by Drobish, D. G.

Cyclophosphamide Treatment of Experimental Allergic Encephalomyelitis in Lewis Rats^1,2,

From the Samuel J. Sackett Research Laboratories and the Infectious Diseases-Hypersensitivity Section, Department of Medicine, Northwestern University-McGaw Medical Center, Chicago, Illinois 60611

Abstract

Cyclophosphamide (CY) treatment (daily doses of 5 or 8 mg/kg for 10 days or less) of Lewis rats with paralytic experimental allergic encephalomyelitis (EAE) results in clinical remission and reversal of histologic evidence of disease in a high proportion of animals. Continued administration of CY is required to maintain these beneficial effects. CY treatment diminishes but does not abolish cutaneous reactivity to tuberculoprotein in Lewis rats sensitized to mycobacteria. On the basis of these and other observations, CY is believed to exert therapeutic effects in EAE by inhibiting proliferation of inflammatory cells and release of injurious factors within the sites of EAE lesions in brain and spinal cord.

Footnotes

¹ This work was supported in part by United States Public Health Service Research Grant NB-06262.

² Aspects of this work were presented before the American Association of Immunologists, Atlantic City, New Jersey, in April, 1970.